Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- N’-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
- Correlated keywords
- 1140909-48-3 BMS907351 Cabometyx XL-184 VEGFR-2 IGF1R Eph-A4 EphB4 cMet cKit FLT-3 Tie-2 HMVEC MDAMB-231 MDAMB231
- Product Overview:
XL184 is an inhibitor of VEGFR2 (IC50 = 0.035 nM).{29857} It is selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4, but also inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively). XL184 (4.6 nM) inhibits VEGF-induced tubule formation in human microvascular endothelial cells (HMVECs). It reduces migration and invasion of B16/F10 melanoma cells induced by hepatocyte growth factor (HGF) when used at a concentration of 123 nM. XL184 (60 mg/kg) induces tumor regression in an MDA-MB-231 breast cancer mouse xenograft model. Unlike sunitinib (Item No. 13159), XL184 does not increase the number of pulmonary tumor foci in an MDA-MB-231 mouse metastasis model. It also protects primary placental fibroblasts from Zika virus infection.{34686} Formulations containing XL184 have been used in the treatment of renal cell and hepatocellular carcinomas.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.